SCHEMBL4038255

SCHEMBL4038255

c1ccc2[nH]c(-c3n[nH]c4ncccc34)nc2c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 3/20 0.68
FLT1 P17948 3/20 0.68
CLK2 P49760 2/20 0.58
DYRK1A Q13627 2/20 0.58
WNT1 P04628 1/20 0.58
TGFBR1 P36897 1/20 0.58
CLK3 P49761 1/20 0.58
PDPK1 O15530 4/20 0.58
CHEK1 O14757 3/20 0.53
KDM4E B2RXH2 4/20 0.51
NPC1 O15118 3/20 0.51
RAB9A P51151 3/20 0.51
ALDH1A1 P00352 3/20 0.51
HPGD P15428 2/20 0.51
PKM P14618 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
HSD17B10 Q99714 2/20 0.51
METAP2 P50579 2/20 0.51
LMNA P02545 1/20 0.51
MTOR P42345 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17557500 0.87 FGFR1 (0.49) FGFR1FLT1CLK2DYRK1AWNT1
SCHEMBL29384149 0.87 FGFR1 (0.49) FGFR1FLT1CLK2DYRK1AWNT1
SCHEMBL12369819 0.86 CLK2 (0.55) FGFR1FLT1CLK2DYRK1AWNT1
SCHEMBL29714866 0.86 CLK2 (0.50) FGFR1FLT1CLK2DYRK1AWNT1
SCHEMBL17555908 0.86 CLK2 (0.50) FGFR1FLT1CLK2DYRK1AWNT1
SCHEMBL3535294 0.83 FGFR1 (0.68) FGFR1FLT1CLK2DYRK1AWNT1
SCHEMBL29714871 0.83 FGFR1 (0.68) FGFR1FLT1CLK2DYRK1AWNT1
SCHEMBL311148 0.82 FGFR1 (1.00) FGFR1FLT1CLK2DYRK1AWNT1
SCHEMBL29714859 0.82 FGFR1 (1.00) FGFR1FLT1CLK2DYRK1AWNT1
SCHEMBL4038389 0.81 CLK2 (0.68) FGFR1FLT1CLK2DYRK1AWNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110190290-A1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF EPITHERIX, LLC (US) 2011-08-04 US disclosed
US-7541367-B2 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders JANSSEN PHARMACEUTICA, N.V. (BE) 2009-06-02 US disclosed
US-20090048249-A1 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders JANSSEN PHARMACEUTICA, N.V. (BE) 2009-02-19 US disclosed
WO-2006130673-A1 3-BENZOIMIDAZOLYL-PYRAZOLOPYRIDINES USEFUL IN TREATING KINASE DISORDERS JANSSEN PHARMACEUTICA, N.V. (BE) 2006-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190290-A1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF BRCA1, THPO, PDXK FGFR1 1304/4885FLT1 985/4885CLK2 2380/4885
US-20090048249-A1 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders PRKDC, PRKACA, ABL1 FGFR1 508/4885FLT1 860/4885CLK2 303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.